Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD123+CLL-1 dual-target CAR-T cells + CD7 CAR-T cells
- Development stage
- Phase 1
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD123+CLL-1 dual-target CAR-T cells + CD7 CAR-T cells is an investigational combination cell therapy regimen being developed by the Institute of Hematology & Blood Diseases Hospital in China. The regimen consists of two distinct chimeric antigen receptor (CAR) T-cell products: **JY017**, which targets both CD123 (IL-3 receptor alpha) and CLL-1 (C-type lectin-like molecule-1), and **JY008**, which targets CD7. This sequential infusion strategy is designed for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). In the clinical protocol, patients first receive JY017 to address the primary leukemic burden; those who do not achieve minimal residual disease (MRD) negativity are subsequently treated with JY008. This multi-target approach is intended to mitigate antigen escape and serve as a bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Other names
- CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells
02
Targets
IL3RA (Interleukin 3 Receptor)CD7 (CD7 antigen)CLEC12A
Beyond the preview
Go deeper on CD123+CLL-1 dual-target CAR-T cells + CD7 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD123+CLL-1 dual-target CAR-T cells + CD7 CAR-T cells.